FDA re­view­ers head back to White Oak in 2023, with lead­er­ship look­ing to ap­pease a new Con­gress

Re­pub­li­cans have tak­en a stand against the pan­dem­ic era habit of lax work-from-home sched­ules. Now that they’ve wres­tled con­trol of the House ma­jor­i­ty, the FDA’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER